Physician profile
Bethany Mello
NPI 1033479696
$4,691.83
in general payments reported to CMS, 2019-2025
16 companies · $3,623 in 2025
The $3,623 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $185 · 2022: $51.38 · 2023: $73.36 · 2024: $759 · 2025: $3,623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $3,156 · Food and Beverage: $1,300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $3,156.00 |
| Food and Beverage | $1,299.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $3,156.00 | 2025 | Nexplanon |
| Amgen INC. | $619.36 | 2024-2025 | Repatha, Repatha |
| Abbvie INC. | $258.21 | 2021-2025 | |
| Becton, Dickinson and Company | $169.62 | 2024 | |
| Lilly USA, LLC | $107.41 | 2021-2025 | Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $82.65 | 2024 | Tezspire |
| Novo Nordisk INC | $73.21 | 2025 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $36.54 | 2024 | Veozah |
| Shield Therapeutics INC | $32.93 | 2024 | |
| Idorsia Pharmaceuticals US INC | $32.01 | 2023 | Quviviq |
| Hologic Sales and Service, LLC | $31.94 | 2021-2023 | Thinprep 2000 Processor, Aptima |
| Myriad Genetic Laboratories, INC. | $22.76 | 2023 | Myrisk |
| Echosens North America, INC. | $20.21 | 2025 | Fibroscan |
| Biohaven Pharmaceutical Holding Company LTD. | $18.89 | 2022 | |
| Lucid Diagnostics INC. | $15.30 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acella Pharmaceuticals, LLC | $14.79 | 2025 | NP Thyroid 60 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bethany Mello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.